MA32634B1 - Polytherapie destinee a traiter une infection par le vhc - Google Patents
Polytherapie destinee a traiter une infection par le vhcInfo
- Publication number
- MA32634B1 MA32634B1 MA33700A MA33700A MA32634B1 MA 32634 B1 MA32634 B1 MA 32634B1 MA 33700 A MA33700 A MA 33700A MA 33700 A MA33700 A MA 33700A MA 32634 B1 MA32634 B1 MA 32634B1
- Authority
- MA
- Morocco
- Prior art keywords
- infection
- vhc
- artemisinin
- treatment
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cette invention concerne des combinaisons thérapeutiques comprenant (a) le composé (1), ou un sel pharmaceutiquement acceptable de celui-ci, tel que ci-décrit, (b) un interféron alpha et (c) de la ribavirine. Le composé (1) est un inhibiteur sélectif et puissant de la sérine protéase ns3 du vhc. La présente invention concerne également des procédés d'utilisation desdites combinaisons thérapeutiques pour traiter une infection par le vhc ou soulager un ou plusieurs de ses symptômes chez un patient.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9775308P | 2008-09-17 | 2008-09-17 | |
US10903308P | 2008-10-28 | 2008-10-28 | |
US17193509P | 2009-04-23 | 2009-04-23 | |
PCT/US2009/056771 WO2010033443A1 (fr) | 2008-09-17 | 2009-09-14 | Polythérapie destinée à traiter une infection par le vhc |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32634B1 true MA32634B1 (fr) | 2011-09-01 |
Family
ID=41571875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33700A MA32634B1 (fr) | 2008-09-17 | 2011-03-14 | Polytherapie destinee a traiter une infection par le vhc |
Country Status (25)
Country | Link |
---|---|
US (1) | US8399484B2 (fr) |
EP (1) | EP2337583A1 (fr) |
JP (1) | JP5539363B2 (fr) |
KR (1) | KR20110054003A (fr) |
CN (1) | CN102159245B (fr) |
AR (1) | AR073516A1 (fr) |
AU (1) | AU2009293493B2 (fr) |
BR (1) | BRPI0918653A2 (fr) |
CA (1) | CA2737376A1 (fr) |
CL (1) | CL2011000571A1 (fr) |
CO (1) | CO6351753A2 (fr) |
EA (1) | EA019965B1 (fr) |
EC (1) | ECSP11010877A (fr) |
HK (1) | HK1156865A1 (fr) |
IL (1) | IL210152A0 (fr) |
MA (1) | MA32634B1 (fr) |
MX (1) | MX2011002602A (fr) |
MY (1) | MY152824A (fr) |
NZ (1) | NZ591030A (fr) |
PE (1) | PE20110343A1 (fr) |
TW (1) | TWI454263B (fr) |
UA (1) | UA103496C2 (fr) |
UY (1) | UY32124A (fr) |
WO (1) | WO2010033443A1 (fr) |
ZA (1) | ZA201009151B (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
JP5539363B2 (ja) | 2008-09-17 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | インターフェロンおよびリバビリンとのhcvns3プロテアーゼ阻害剤の組合せ |
AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
CN102741270B (zh) * | 2009-09-28 | 2015-07-22 | 英特穆恩公司 | C型肝炎病毒复制的环肽抑制剂 |
NZ598465A (en) * | 2009-10-30 | 2013-10-25 | Boehringer Ingelheim Int | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
CA2813093A1 (fr) * | 2010-09-30 | 2012-04-05 | Boehringer Ingelheim International Gmbh | Therapie combinee pour le traitement d'une infection par le vhc |
EP2658859A4 (fr) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | Inhibiteurs macrocycliques de sérine protéase d'hépatite c |
MX2013007698A (es) | 2010-12-30 | 2013-08-15 | Abbvie Inc | Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina. |
AU2012205777A1 (en) * | 2011-01-10 | 2013-08-01 | Proteus Digital Health, Inc. | System, method, and article to prompt behavior change |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
CN104383541A (zh) | 2011-10-21 | 2015-03-04 | 艾伯维公司 | 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法 |
DK2583680T1 (da) | 2011-10-21 | 2015-01-19 | Abbvie Inc | Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
JP2015509980A (ja) * | 2012-03-14 | 2015-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Hcv−hiv同時感染患者集団のhcv感染症を治療するための併用療法 |
US20140242029A1 (en) * | 2013-02-27 | 2014-08-28 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
WO2013147750A1 (fr) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Polythérapie orale pour le traitement d'une infection au vhc dans une sous-population de patients spécifiques |
WO2013147749A1 (fr) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Polythérapie orale pour le traitement d'une infection au vhc dans des populations de sous-génotypes de patients spécifiques |
JP2015512900A (ja) * | 2012-03-28 | 2015-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特別な患者の遺伝子亜型分集団のhcv感染症を治療するための併用療法 |
WO2014138374A1 (fr) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Polythérapie par voie orale pour le traitement d'une infection par le vhc chez une sous-population spécifique de patients |
WO2015103490A1 (fr) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Formes galéniques antivirales solides |
CA3022119A1 (fr) | 2016-04-28 | 2017-11-02 | Emory University | Compositions therapeutiques a base de nucleotides et nucleosides contenant un alcyne et utilisations associees |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4247479A (en) | 1976-12-03 | 1981-01-27 | Hoechst Aktiengesellschaft | Process for the manufacture of aromatic amines from α, β-unsaturated cycloaliphatic ketoximes |
US6387365B1 (en) | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
CA2236591C (fr) | 1995-11-02 | 2012-01-03 | Schering Corporation | Therapie par perfusion continue a faible dosage de cytokine |
US6472373B1 (en) | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
US6172046B1 (en) | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
PL192364B1 (pl) | 1998-06-08 | 2006-10-31 | Hoffmann La Roche | Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US6824768B2 (en) | 1998-12-18 | 2004-11-30 | Schering Corporation | Ribavirin-pegylated interferon alfa induction HCV combination therapy |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
US6849254B1 (en) | 1999-04-19 | 2005-02-01 | Schering Corporation | HCV combination therapy |
ATE367379T1 (de) | 2000-08-09 | 2007-08-15 | Hoffmann La Roche | Quinolin-derivate als antientzündungsmittel |
EP2335700A1 (fr) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic |
US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US7601709B2 (en) | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
CA2521835A1 (fr) | 2003-04-10 | 2004-10-21 | Boehringer Ingelheim International Gmbh | Procede pour preparer des composes macrocycliques par reaction de metathese catalysee par complexe de ruthenium |
WO2004092203A2 (fr) | 2003-04-10 | 2004-10-28 | Boehringer Ingelheim International, Gmbh | Procede de preparation de composes macrocycliques |
ES2386161T3 (es) | 2003-04-16 | 2012-08-10 | Bristol-Myers Squibb Company | Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima |
CN1791599A (zh) | 2003-05-21 | 2006-06-21 | 贝林格尔.英格海姆国际有限公司 | 丙型肝炎抑制剂化合物 |
CN1835765A (zh) | 2003-08-13 | 2006-09-20 | 霍华德·J·史密斯及同仁控股有限公司 | 治疗病毒感染的方法 |
US7642235B2 (en) | 2003-09-22 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
AR045870A1 (es) | 2003-10-11 | 2005-11-16 | Vertex Pharma | Terapia de combinacion para la infeccion de virus de hepatitis c |
US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
US7410979B2 (en) | 2003-11-19 | 2008-08-12 | Rigel Pharmaceuticals, Inc. | Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections |
ES2431314T3 (es) | 2004-02-20 | 2013-11-26 | Boehringer Ingelheim International Gmbh | Inhibidores de polimerasa vírica |
CA2556917C (fr) | 2004-03-15 | 2013-07-09 | Boehringer Ingelheim International, Gmbh | Procede de preparation de composes macrocycliques |
EA012389B1 (ru) | 2004-03-30 | 2009-10-30 | Интермун, Инк. | Макроциклические соединения в качестве ингибиторов вирусной репликации |
CA2568008C (fr) | 2004-05-25 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Processus de preparation d'inhibiteurs de protease hcv acyclique |
DE102004033312A1 (de) | 2004-07-08 | 2006-01-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren |
CN1984671A (zh) | 2004-07-14 | 2007-06-20 | 诺瓦提斯公司 | 环孢菌素和peg化干扰素的组合用于治疗丙型肝炎病毒(hcv)的用途 |
CA2577831A1 (fr) | 2004-09-17 | 2006-03-30 | Boehringer Ingelheim International Gmbh | Procede de fabrication d'inhibiteurs de protease hcv macrocycliques |
EP1794179A1 (fr) | 2004-09-17 | 2007-06-13 | Boehringer Ingelheim International Gmbh | Réaction de métathèse cyclisante en milieu fluide supercritique |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
JP2009526070A (ja) | 2006-02-09 | 2009-07-16 | シェーリング コーポレイション | Hcvプロテアーゼ阻害薬とhcvポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法 |
WO2008070358A2 (fr) * | 2006-11-16 | 2008-06-12 | Phenomix Corporation | Inhibiteurs de la sérine protéase de l'hépatite c et utilisations de ceux-ci |
TW200914013A (en) | 2007-06-29 | 2009-04-01 | Gilead Sciences Inc | Antiviral compounds |
AP2874A (en) | 2007-06-29 | 2014-03-31 | Gilead Sciences Inc | Antiviral compounds |
WO2009014730A1 (fr) | 2007-07-26 | 2009-01-29 | Idenix Pharmaceuticals, Inc. | Inhibiteurs macrocycliques de la sérine protéase |
WO2009021121A2 (fr) | 2007-08-08 | 2009-02-12 | Wyeth | Identification et caractérisation de variants de réplicon de vhc présentant une sensibilité réduite à une combinaison d'inhibiteurs de polymérase et de protéase, et procédés connexes |
MX2010008523A (es) | 2008-02-04 | 2010-08-31 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa. |
PE20110388A1 (es) | 2008-09-16 | 2011-07-01 | Boehringer Ingelheim Int | Formas cristalinas de un derivado de peptido como inhibidores de hcv |
JP5539363B2 (ja) | 2008-09-17 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | インターフェロンおよびリバビリンとのhcvns3プロテアーゼ阻害剤の組合せ |
TW201023858A (en) | 2008-09-18 | 2010-07-01 | Ortho Mcneil Janssen Pharm | Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside |
PT2451438E (pt) | 2009-07-07 | 2014-03-26 | Boehringer Ingelheim Int | Composição farmacêutica para um inibidor de protease viral da hepatite c |
NZ598465A (en) | 2009-10-30 | 2013-10-25 | Boehringer Ingelheim Int | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
CA2813093A1 (fr) | 2010-09-30 | 2012-04-05 | Boehringer Ingelheim International Gmbh | Therapie combinee pour le traitement d'une infection par le vhc |
-
2009
- 2009-09-14 JP JP2011527889A patent/JP5539363B2/ja not_active Expired - Fee Related
- 2009-09-14 WO PCT/US2009/056771 patent/WO2010033443A1/fr active Application Filing
- 2009-09-14 MY MYPI20111139 patent/MY152824A/en unknown
- 2009-09-14 BR BRPI0918653A patent/BRPI0918653A2/pt not_active IP Right Cessation
- 2009-09-14 KR KR1020117005679A patent/KR20110054003A/ko not_active Application Discontinuation
- 2009-09-14 AU AU2009293493A patent/AU2009293493B2/en not_active Ceased
- 2009-09-14 CA CA2737376A patent/CA2737376A1/fr not_active Abandoned
- 2009-09-14 UA UAA201104531A patent/UA103496C2/uk unknown
- 2009-09-14 EA EA201100506A patent/EA019965B1/ru not_active IP Right Cessation
- 2009-09-14 EP EP09792492A patent/EP2337583A1/fr not_active Withdrawn
- 2009-09-14 CN CN2009801362929A patent/CN102159245B/zh not_active Expired - Fee Related
- 2009-09-14 MX MX2011002602A patent/MX2011002602A/es active IP Right Grant
- 2009-09-14 PE PE2011000635A patent/PE20110343A1/es not_active Application Discontinuation
- 2009-09-14 NZ NZ591030A patent/NZ591030A/xx not_active IP Right Cessation
- 2009-09-16 UY UY0001032124A patent/UY32124A/es not_active Application Discontinuation
- 2009-09-16 TW TW098131293A patent/TWI454263B/zh not_active IP Right Cessation
- 2009-09-16 US US12/560,752 patent/US8399484B2/en active Active
- 2009-09-16 AR ARP090103556A patent/AR073516A1/es unknown
-
2010
- 2010-12-20 ZA ZA2010/09151A patent/ZA201009151B/en unknown
- 2010-12-21 IL IL210152A patent/IL210152A0/en unknown
-
2011
- 2011-03-09 EC EC2011010877A patent/ECSP11010877A/es unknown
- 2011-03-14 MA MA33700A patent/MA32634B1/fr unknown
- 2011-03-16 CO CO11032826A patent/CO6351753A2/es not_active Application Discontinuation
- 2011-03-17 CL CL2011000571A patent/CL2011000571A1/es unknown
- 2011-10-20 HK HK11111257.2A patent/HK1156865A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20110054003A (ko) | 2011-05-24 |
TW201016218A (en) | 2010-05-01 |
EP2337583A1 (fr) | 2011-06-29 |
PE20110343A1 (es) | 2011-06-25 |
ECSP11010877A (es) | 2011-04-29 |
BRPI0918653A2 (pt) | 2015-12-01 |
ZA201009151B (en) | 2011-09-28 |
AR073516A1 (es) | 2010-11-10 |
AU2009293493B2 (en) | 2014-09-18 |
EA019965B1 (ru) | 2014-07-30 |
NZ591030A (en) | 2012-10-26 |
UA103496C2 (uk) | 2013-10-25 |
JP5539363B2 (ja) | 2014-07-02 |
TWI454263B (zh) | 2014-10-01 |
CN102159245B (zh) | 2013-07-24 |
US20100068182A1 (en) | 2010-03-18 |
MX2011002602A (es) | 2011-04-07 |
UY32124A (es) | 2010-04-30 |
CA2737376A1 (fr) | 2010-03-25 |
MY152824A (en) | 2014-11-28 |
CL2011000571A1 (es) | 2011-07-29 |
CO6351753A2 (es) | 2011-12-20 |
HK1156865A1 (en) | 2012-06-22 |
EA201100506A1 (ru) | 2011-10-31 |
CN102159245A (zh) | 2011-08-17 |
US8399484B2 (en) | 2013-03-19 |
AU2009293493A1 (en) | 2010-03-25 |
WO2010033443A1 (fr) | 2010-03-25 |
JP2012502999A (ja) | 2012-02-02 |
IL210152A0 (en) | 2011-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32634B1 (fr) | Polytherapie destinee a traiter une infection par le vhc | |
MA33806B1 (fr) | Inhibiteurs du virus de l'hepatite c | |
EA200970805A1 (ru) | Ингибиторы серинпротеаз для лечения hcv инфекций | |
EA200900969A1 (ru) | Макроциклические ингибиторы протеазы гепатита с | |
EA200901101A1 (ru) | Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс | |
EA200900298A1 (ru) | Ингибиторы вируса гепатита с | |
CY1114356T1 (el) | Αναστολεις του ιου της ηπατιτιδας c | |
EA200901241A1 (ru) | Соединения для лечения гепатита с | |
EA201200890A1 (ru) | Комбинированная терапия hcv | |
WO2007089618A3 (fr) | Inhibiteurs de la sérine protéase de l'hépatite c et leurs utilisations | |
MY141003A (en) | Materials and methods for treating viral infections with a cysteamine compound | |
ATE547103T1 (de) | Hemmer des hepatitis-c-virus | |
WO2008106058A3 (fr) | Inhibiteurs de sérine protéases | |
ATE512976T1 (de) | Hemmer des hepatitis-c-virus | |
EA200800371A1 (ru) | Ингибиторы ns3 протеазы вгс | |
CY1111212T1 (el) | Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ | |
WO2006130627A3 (fr) | Methodes de traitement de l'hepatite c | |
EA200700243A1 (ru) | Способы лечения гепатита с | |
EA200802346A1 (ru) | Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с | |
EA200500584A1 (ru) | Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c | |
MX2013003634A (es) | Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales. | |
NO20075655L (no) | Terapeutisk RNAI for respiratorisk virusinfeksjon | |
WO2008036899A3 (fr) | Procédés d'élimination des contaminants viraux durant la purification des protéines | |
AU2012332832A8 (en) | Compositions useful for the treatment of viral diseases | |
EA201200650A1 (ru) | Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин |